Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECIPE-2: Rituximab in refractory IgG4 autoantibody-positive CIDP
jRCTs041210046Completed
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Primary endpoint: Adjusted INCAT Disability Scale. Started Aug 2021; status: completed.
02
Drugs
rituximab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCTs041210046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210046.